When cancer spreads to the lungs from another part of the body, tumor cells form new growths called lung metastases that can interfere with breathing, cause fluid buildup, and significantly change your treatment plan. This is different from lung cancer that starts in the lungs. The most common cancers that spread to the lungs are colorectal (about 26% of cases), head and neck cancers (19%), urologic cancers like kidney or prostate (15%), other gastrointestinal cancers (11%), and breast cancer (roughly 10%).
How Cancer Reaches the Lungs
Your lungs are one of the most common landing spots for cancer that has spread, and there’s a straightforward reason: every drop of blood in your body passes through the lungs to pick up oxygen. Cancer cells that break free from a primary tumor and enter the bloodstream are essentially filtered through the dense network of tiny blood vessels in lung tissue. Some of those cells lodge there, survive, and begin to grow.
Before cancer cells even arrive, the primary tumor can prepare the ground. Tumors release tiny packages called extracellular vesicles into the bloodstream that travel ahead and remodel distant tissue, making it more hospitable for incoming cancer cells. Research has shown that these vesicles can reprogram the supportive tissue in the lungs, reshaping the surrounding structure into what scientists call a “pre-metastatic niche.” By the time cancer cells arrive, the environment is already primed to support their growth.
What It Feels Like
In the early stages, lung metastases often cause no symptoms at all. Many people learn about them through routine imaging done as part of cancer follow-up, not because they felt something new. As the growths enlarge or multiply, the most common symptoms include a persistent cough that doesn’t respond to typical treatments, shortness of breath that worsens over weeks, and chest pain that may feel sharp or dull depending on where the tumors are located.
Some people develop a condition called malignant pleural effusion, where fluid accumulates in the space between the lungs and the chest wall. This fluid compresses lung tissue and can make breathing feel labored even at rest. Pleural effusions tied to metastatic cancer reduce average survival to about 3 to 4 months and significantly affect daily quality of life, making management of the fluid itself an important part of care.
How Lung Metastases Affect Breathing
Your lungs exchange oxygen and carbon dioxide through millions of tiny air sacs called alveoli, each wrapped in a web of blood vessels thinner than a hair. Metastatic tumors disrupt this system in several ways. Growths inside the lung tissue can fill or collapse alveoli, forcing blood to pass through without picking up oxygen. This is called shunting, and it can cause oxygen levels to drop significantly.
Tumors can also thicken the walls of alveoli, slowing the transfer of gases so that blood leaves the lungs only partially oxygenated. When growths block or compress blood vessels, some areas of the lung receive air but no blood flow, creating “dead space” that wastes each breath. The combined effect is that your lungs become less efficient, leading to fatigue, breathlessness during light activity, and in advanced cases, respiratory failure.
How Doctors Find and Identify Them
CT scans of the chest are the standard tool for detecting lung metastases. Metastatic nodules typically appear as multiple round spots scattered through both lungs, often concentrated near the outer edges and lower sections. This pattern of bilateral, rounded nodules is a hallmark that distinguishes metastatic disease from a new primary lung cancer, which usually appears as a single mass.
One distinctive pattern is called miliary metastasis: more than 20 tiny nodules, most smaller than 5 millimeters, spread diffusely and randomly across both lungs. This pattern signals that cancer has spread through the bloodstream rather than through nearby lymph tissue. Among lung cancers that show this pattern, adenocarcinoma is by far the most common subtype, accounting for about 23% of cases with miliary spread. PET scans, which detect areas of high metabolic activity, and biopsies of the lung nodules help confirm whether the growths match the original cancer type.
Treatment Approaches
Treatment depends heavily on how many metastases are present and how widely they’re distributed. The key distinction is between oligometastatic disease, where cancer is limited to a small number of spots, and polymetastatic disease, generally defined as six or more metastases.
For oligometastatic disease, a concept first described in 1995, there is a possibility of long-term control or even cure. Treatment typically combines systemic therapy (such as chemotherapy, immunotherapy, or targeted therapy delivered through the bloodstream) with local treatments aimed directly at the lung tumors. One common local option is stereotactic body radiotherapy, which delivers high-dose, precisely targeted radiation to individual tumors over a few sessions. Surgery to remove isolated lung metastases is another option when the number and location of tumors allow it.
For widespread metastatic disease, the focus shifts to systemic therapy designed to slow cancer growth throughout the body. The choice of systemic treatment depends on the original cancer type, its genetic characteristics, and how well it has responded to prior treatment. In cases where systemic therapy is already working well, adding local treatment to the lungs may not offer additional benefit. But when systemic options are losing effectiveness, targeting specific lung tumors with radiation can help maintain disease control.
Managing Fluid Buildup
When malignant pleural effusion develops, draining the fluid is often one of the first steps. A procedure called thoracentesis uses a needle or small catheter to remove fluid through the chest wall. For diagnostic purposes, about 250 milliliters is enough, but for symptom relief, up to 1,500 milliliters is commonly drained in a single session. The relief can be immediate, but the fluid often returns.
To prevent reaccumulation, doctors may perform pleurodesis, a procedure that seals the space where fluid collects. A chest tube first drains the fluid completely, then a sclerosing agent (talc is the most widely used) is introduced to irritate the lung lining and cause it to adhere to the chest wall, eliminating the space where fluid gathers. This can be done at the bedside or through a minimally invasive camera-guided procedure under sedation.
A newer alternative is an indwelling pleural catheter, a small silicone tube placed under the skin with a one-way valve that allows you to drain fluid at home on a regular schedule. This avoids repeated hospital visits and gives you more control over symptom management. Some treatment plans combine both approaches, performing pleurodesis during catheter placement for faster and more durable results.
Outlook and Survival
Survival after cancer spreads to the lungs varies enormously depending on the original cancer type, the number and size of metastases, how the cancer responds to treatment, and your overall health. There is no single statistic that applies to everyone. Oligometastatic disease with only a few targetable tumors carries a meaningfully better prognosis than widespread involvement across both lungs.
Advances in targeted therapies and immunotherapy have changed the outlook for certain cancer subtypes dramatically over the past decade. Cancers with specific genetic mutations, such as certain breast cancers or colorectal cancers, may respond well to therapies designed to exploit those mutations, sometimes controlling metastatic disease for years. The pace of improvement in treatment options means that statistics from even five years ago may not reflect what’s achievable today.